Share
1,068 Posts.
lightbulb Created with Sketch. 137
clock Created with Sketch.
23/11/18
11:50
Share
Originally posted by Torpy
↑
PAR
Paradigm Biopharma - under the radar but pretty big announcement today. Acquired a license to another indication worth $Bs per annum once commercialised. Acquisition includes successful Phase 2a data. Attractive terms (no dilution, small upfront fully funded by recent placement, single digit royalties). Synergies with their main target of OsteoArthritis so complimentary body of data, helping with submissions. Pretty much just doubled their prospective market, added another shot on goal, and a potential short path to market being an orphan indication. "High probability of developing a commercial product".
Expand
PAR
Starting a multi-day run. Volumes are increasing. Latest news being digested. AGM on Monday should provide more colour. Thanksgiving overnight has US investors asleep til next week....